Travere Therapeutics, Inc.
NASDAQTravere Therapeutics arrives at the close of this week carrying two competing stories: a Q1 earnings beat that pulled the entire sell-side to raise its targets, and a cluster of insider sales from the same management team that just delivered the good news. The catalyst is clear. Q1 results hit Tuesday, and the stock beat EPS estimates by $0.29. The reaction was immediate: five…
Snapshot as of 6 May 2026
Travere Therapeutics arrives at the close of this week carrying two competing stories: a Q1 earnings beat that pulled the entire sell-side to raise its targets, and a cluster of insider sales from the same management…
Travere Therapeutics heads into its May 7 earnings with a striking divergence: short sellers have been exiting while analysts race to raise targets, leaving the stock 47% higher than a month ago with defensive options…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for TVTX — free to start on ORTEX.
Sign up for free →Open TVTX on ORTEX